Hedonin (Quetiapine)

Hedonin (quetiapine) is indicated for several psychiatric disorders where modulation of dopamine and serotonin pathways is beneficial.

• Schizophrenia, including acute and maintenance phases.
• Bipolar I disorder, both manic and depressive episodes.
• Adjunctive therapy for major depressive disorder when additional symptom control is needed.
• Prevention of relapse in patients with stable schizophrenia.
• Management of agitation associated with psychotic conditions.
• Off‑label or clinical trial use for generalized anxiety disorder or post‑traumatic stress disorder, as determined by a prescriber.

Side effects of Hedonin vary in frequency and severity; they are grouped here for reference.

Common

• Sedation or somnolence.
• Dizziness or light‑headedness, especially when standing.
• Dry mouth and increased thirst.
• Weight gain or increased appetite.
• Constipation.
• Orthostatic hypotension.

Serious

• Agranulocytosis or severe neutropenia.
• Neuroleptic malignant syndrome.
• Suicidal thoughts or behavior, particularly in younger adults.
• Severe hypotension or cardiovascular collapse.
• Extrapyramidal symptoms such as severe akathisia.

Before starting Hedonin, clinicians should evaluate several safety considerations to minimize risk.

• Assess cardiovascular status, especially a history of arrhythmias or orthostatic hypotension.
• Monitor metabolic parameters such as weight, fasting glucose, and lipid profile regularly.
• Screen for a personal or family history of seizures or conditions that lower seizure threshold.
• Use caution in elderly patients due to an increased risk of falls and sedation.
• Evaluate pregnancy or breastfeeding status; safety data are limited.
• Consider gradual dose reduction when discontinuing to avoid withdrawal or rebound symptoms.

Quetiapine can interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid

• Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may raise quetiapine plasma concentrations.
• Combining with other central nervous system depressants (e.g., benzodiazepines, opioids) can increase sedation and respiratory depression.

Use with caution

• CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce quetiapine effectiveness.
• Co‑administration with antihypertensive agents may enhance orthostatic hypotension.
• Concurrent anticholinergic drugs may worsen dry mouth and constipation.
• Caution with other serotonergic agents due to a theoretical risk of serotonin syndrome.
• Monitor lithium levels if used together, as quetiapine may affect renal clearance.